Navigation Links
Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:10/22/2008

ate, 120 patients have been enrolled in the trial with enrollment completed at doses up to 360 mg/day. A total of 73 patients in the three lowest expanded dose groups (60, 150, and 240 mg/day) have been followed for more than 24 weeks. Of these 73 patients, 31 patients (42 percent) have received MDV3100 for greater than 24 weeks.

At 12 weeks, the recommended time point for reporting PSA-based outcomes, 36 of 73 patients (49 percent) had a greater than 50 percent decline in PSA compared to their baseline value. Patients also saw improvements as measured by radiographic changes and reductions in the number of CTCs to favorable counts, including 38 percent of patients with evaluable soft tissue lesions in the 240 mg/day cohort showing a partial response at 24 weeks. The data suggest a dose-response trend with a higher percentage of patients in the 240 mg/day dose cohort experiencing 90 percent reduction in PSA levels, radiographic partial responses and conversions to favorable CTC counts of less than five post-treatment.

"We are excited by the PSA decreases and radiographic findings observed with MDV3100 in the trial to date. Moreover, the positive shift observed in CTC counts and radiographic images suggests concordance of the data," said David Hung, M.D., president and chief executive officer of Medivation. "As the 240 mg/day dose has been well tolerated and appears to be the most effective, we are continuing to escalate the dose, with the 360 mg/day expansion group completely enrolled, dose escalation in progress at 480 mg/day, and initial dosing starting at 600 mg/day."

The Company expects to seek U.S. Food and Drug Administration agreement to begin a pivotal Phase 3 registration study in castration-resistant prostate cancer patients in 2009.

The data were presented today in a poster session at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva. Abstract no: 160.

About Prostate Cancer and MD
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
2. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
3. Medivation Announces Participation in Upcoming Conferences
4. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
5. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Senior Management Promotions
9. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
10. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... ANGELES , May 26, 2015 Mr. ... his family, thanks President Barack Obama and President ... during the time of loss of Dr. Rongxiang Xu ... humanitarian and a leader ahead of his time, Dr. Xu,s ... the community leave a legacy that will not be forgotten. ...
(Date:5/26/2015)... NEW YORK , May 26, 2015 ... NVGN ), announced today that it will present at the ... New York City at the Grand Hyatt ... Kelly , Novogen Chairman and CEO, is scheduled to begin at ... To access the webcast, go to http://wsw.com/webcast/marcum3/nvgn . ...
(Date:5/25/2015)... 2015 The 2015 Market Research ... a professional and in-depth study on the current ... with a focus on the Chinese situation. ... research are Linde Industrial Gas, Basf, Air Products, ... Xinlong Group, Longsheng Group, Juhua Group, Wandali Gas, ...
(Date:5/22/2015)... Warren, NJ (PRWEB) May 22, 2015 ... a new white paper that explores the potential of ... industries. The white paper was developed to help life ... they can leverage data to gain critical business insights. ... generated large amounts of data driven by patient profiling, ...
Breaking Biology Technology:Dr. Rongxiang Xu, Beyond A Legend 2Novogen to Present at the 2015 Marcum Microcap Conference 2Novogen to Present at the 2015 Marcum Microcap Conference 3Novogen to Present at the 2015 Marcum Microcap Conference 4Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 2Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 3New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY), announced ... will participate in two separate presentations at the,BIO 2008 ... a corporate overview of the,Company on Tuesday, June 17th ... On Wednesday, June 18th at 4:00 p.m. PT, ...
... NEWARK, N.J., June 12 BioNeutral announced today ... kill anthrax,spores on contact. This chemical technology is ... responders in conjunction with any suspected anthrax,exposure. "The ... formulation in as little as 15 seconds," said ...
... Senesco,Technologies, Inc. ("Senesco" or the "Company") (Amex: ... be presenting at the Business Forum during BIO ... being held at the San Diego Convention Center ... of Senesco, will deliver the,Company,s corporate presentation on ...
Cached Biology Technology:Oncolytics Biotech Inc. to Present at BIO 2008 International Convention 2BioNeutral Announces a BREAKTHROUGH in the Fight Against Bioterrorism 2Senesco Technologies to Present at BIO 2008 Business Forum 2
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... of widespread genetic sequencing, the ability to edit and alter ... information within and how it guides biological function. ... issue of the journal GENETICS takes genome editing ... level of fine control and, importantly, the transmission of those ...
... device invented at UCLA that conducts kidney tests and ... the need for frequent office visits by people with ... The smartphone-based device was developed in the research ... and bioengineering at the UCLA Henry Samueli School of ...
... study confirms that exposure to low to moderate amounts ... Doses of about 120 parts per billion of arsenic ... safeproduced lung damage comparable to decades of smoking tobacco. ... This is the first population-based study to clearly ...
Cached Biology News:Unprecedented control of genome editing in flies promises insight into human development, disease 2Unprecedented control of genome editing in flies promises insight into human development, disease 3UCLA researchers invent portable device for common kidney tests 2Study adds lung damage to harmful effects of arsenic 2Study adds lung damage to harmful effects of arsenic 3Study adds lung damage to harmful effects of arsenic 4
Alexa Fluor 647 anti-mouse IL-12 (Interleukin-12) / IL-23 (Interleukin-23) p40 25 ug...
BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Rabbit polyclonal to Phosphothreonine-X-Phosphotyrosine (HRP) ( Abpromise for all tested applications)....
Biology Products: